Praxis Precision Medicines Inc. (PRAX)
PRAX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/0001689548-26-000029-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRAX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001689548 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$303.3M |
| Operating income | -$326.2M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $357.3M |
| Total assets | $937.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity In accordance with the Financial Accounting Standards Board ( FASB ) Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within " | 10-Q 2026-11-09 |
| Cash and burn | $361.9M cash; operating cash flow -$80.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 27,951,553 (2026-11-04); 25,007,171 a year earlier; 128,550,152 three years earlier. 3y figure adjusted for split (1-for-15 overall). | Cover page 2026-11-04 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2023-11-29 | Source 2023-11-29 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns | Latest 2026-01-07 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-07-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $44.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$94.2M | -$81.7M | $361.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$83.7M | -$77.5M | $474.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$92.6M | -$86.2M | $536.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | $0 | -$88.9M | -$76.3M | $357.3M | No debt tags | $0 | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | $0 | -$73.9M | -$65.1M | $149.5M | No debt tags | $7.5M | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | $0 | -$71.1M | -$54.7M | $157.4M | No debt tags | $7.8M | 10-Q 2025-08-04 |
| Q1 2025 2025-03-31 | $0 | -$69.3M | -$53.0M | $165.6M | No debt tags | $8.1M | 10-Q 2025-05-02 |
| Q4 2024 2024-12-31 | $7.5M | -$58.7M | -$56.1M | $215.4M | No debt tags | $8.6M | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-07 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 515 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.2% |
| 1 month | +34.8% |
| 3 months | -10.9% |
| Year to date | +11.3% |
| 1 year | +84.3% |
| From 52-week high | -15.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
| SYRE | Spyre Therapeutics Inc. | $99.37 | -4.45% | $9.4B |
| SMMT | Summit Therapeutics Inc. Common Stock | $11.82 | -16.47% | $9.5B |
| TGTX | TG Therapeutics Inc. | $62.76 | -2.71% | $9.5B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
| RYTM | Rhythm Pharmaceuticals Inc. | $107.48 | -6.56% | $7.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier